92 related articles for article (PubMed ID: 18501498)
1. Editorial comment on: Molecular cancer phenotype in normal prostate tissue.
Füssel S
Eur Urol; 2009 Apr; 55(4):891. PubMed ID: 18501498
[No Abstract] [Full Text] [Related]
2. Molecular cancer phenotype in normal prostate tissue.
Schlomm T; Hellwinkel OJ; Buness A; Ruschhaupt M; Lübke AM; Chun FK; Simon R; Budäus L; Erbersdobler A; Graefen M; Huland H; Poustka A; Sültmann H
Eur Urol; 2009 Apr; 55(4):885-90. PubMed ID: 18501497
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: expression and prognostic relevance of annexin A3 in prostate cancer.
van Leenders GJ
Eur Urol; 2008 Dec; 54(6):1323. PubMed ID: 18222603
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Mutations in the AXIN1 gene in advanced prostate cancer.
Schalken JA
Eur Urol; 2009 Sep; 56(3):494. PubMed ID: 18514388
[No Abstract] [Full Text] [Related]
6. cDNA microarray analysis of pigment epithelium-derived factor-regulated gene expression profile in prostate carcinoma cells.
Liu W; Wu Z; Guan M; Lu Y
Int J Urol; 2009 Mar; 16(3):323-8. PubMed ID: 19207613
[TBL] [Abstract][Full Text] [Related]
7. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
9. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
11. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
[TBL] [Abstract][Full Text] [Related]
12. Changes in chromatin phenotype predict the response to hormonal deprivation therapy in patients with prostate cancer.
Mohamed M; Greif PA; Diamond J; Sharafeldin O; Maxwell P; Montironi R; O'Brien A; Young M; Hamilton PW
BJU Int; 2009 Feb; 103(3):391-8. PubMed ID: 19021609
[TBL] [Abstract][Full Text] [Related]
13. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
Noonan EJ; Place RF; Pookot D; Basak S; Whitson JM; Hirata H; Giardina C; Dahiya R
Oncogene; 2009 Apr; 28(14):1714-24. PubMed ID: 19252524
[TBL] [Abstract][Full Text] [Related]
14. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
Tamura K; Furihata M; Chung SY; Uemura M; Yoshioka H; Iiyama T; Ashida S; Nasu Y; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Sci; 2009 May; 100(5):914-9. PubMed ID: 19298603
[TBL] [Abstract][Full Text] [Related]
15. [Molecular biology in prostate cancer. Editorial comment].
Fernández Gómez JM
Arch Esp Urol; 2010; 63(1):10-1. PubMed ID: 21109712
[No Abstract] [Full Text] [Related]
16. Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
Alonso V; Neves AF; Marangoni K; Faria PC; Freschi AP; Capaneli AC; Meola J; Goulart LR
Cancer Detect Prev; 2009; 32(4):336-7. PubMed ID: 19026495
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
18. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes.
Böhm M; Locke WJ; Sutherland RL; Kench JG; Henshall SM
Oncogene; 2009 Oct; 28(43):3847-56. PubMed ID: 19684615
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment on: The feasibility of prostate cancer detection by triple spectroscopy.
Da Pozzo LF
Eur Urol; 2009 Feb; 55(2):383-4. PubMed ID: 18359149
[No Abstract] [Full Text] [Related]
20. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
Saha B; Kaur P; Tsao-Wei D; Naritoku WY; Groshen S; Datar RH; Jones LW; Imam SA
Prostate; 2008 Nov; 68(15):1681-8. PubMed ID: 18712716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
